Literature DB >> 15613311

Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.

Christoph A Merten1, Jörn Stitz, Gundula Braun, Eric M Poeschla, Klaus Cichutek, Christian J Buchholz.   

Abstract

In contrast to most gammaretrovirus envelope proteins (Env), the Gibbon ape leukemia virus (GaLV) Env protein does not mediate the infectivity of human immunodeficiency virus type 1 (HIV-1) particles. We made use of this observation to set up a directed evolution system by creating a library of GaLV Env variants diversified at three critical amino acids, all located around the R-peptide cleavage site within the cytoplasmic tail. This library was screened for variants that were able to functionally pseudotype HIV-1 vector particles. All selected Env variants mediated the infectivity of HIV-1 vector particles and encoded novel cytoplasmic tail motifs. They were efficiently incorporated into HIV particles, and the R peptide was processed by the HIV protease. Interestingly, in some of the selected variants, the R-peptide cleavage site had shifted closer to the C terminus. These data demonstrate a valuable approach for the engineering of chimeric viruses and vector particles.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613311      PMCID: PMC538528          DOI: 10.1128/JVI.79.2.834-840.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  In vivo selection of protease cleavage sites from retrovirus display libraries.

Authors:  C J Buchholz; K W Peng; F J Morling; J Zhang; F L Cosset; S J Russell
Journal:  Nat Biotechnol       Date:  1998-10       Impact factor: 54.908

3.  Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity.

Authors:  B A Brody; S S Rhee; E Hunter
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.

Authors:  J Stitz; C J Buchholz; M Engelstädter; W Uckert; U Bloemer; I Schmitt; K Cichutek
Journal:  Virology       Date:  2000-07-20       Impact factor: 3.616

5.  Palmitoylation of the intracytoplasmic R peptide of the transmembrane envelope protein in Moloney murine leukemia virus.

Authors:  K E Olsen; K B Andersen
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

6.  Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors.

Authors:  I Christodoulopoulos; P M Cannon
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Functional domains in the retroviral transmembrane protein.

Authors:  Y Zhao; L Zhu; C A Benedict; D Chen; W F Anderson; P M Cannon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells.

Authors:  H Mochizuki; J P Schwartz; K Tanaka; R O Brady; J Reiser
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

10.  Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.

Authors:  A Rein; J Mirro; J G Haynes; S M Ernst; K Nagashima
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more
  7 in total

1.  Targeted cell entry of lentiviral vectors.

Authors:  Sabrina Funke; Andrea Maisner; Michael D Mühlebach; Ulrike Koehl; Manuel Grez; Roberto Cattaneo; Klaus Cichutek; Christian J Buchholz
Journal:  Mol Ther       Date:  2008-06-24       Impact factor: 11.454

2.  Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.

Authors:  Sanath Kumar Janaka; Tiffany M Lucas; Marc C Johnson
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

3.  Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.

Authors:  Patrick L Sinn; Jeremy E Coffin; Natarajan Ayithan; Kathleen H Holt; Wendy Maury
Journal:  Methods Mol Biol       Date:  2017

4.  Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Authors:  Ilias Christodoulopoulos; Magali E Droniou-Bonzom; Jill E Oldenburg; Paula M Cannon
Journal:  Retrovirology       Date:  2010-01-26       Impact factor: 4.602

5.  Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein.

Authors:  Christoph A Merten; Jörn Stitz; Gundula Braun; Julia Medvedovska; Klaus Cichutek; Christian J Buchholz
Journal:  Nucleic Acids Res       Date:  2006-03-15       Impact factor: 16.971

6.  Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors.

Authors:  B-Y Hwang; D V Schaffer
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

7.  Antisense gene silencing: therapy for neurodegenerative disorders?

Authors:  Troels T Nielsen; Jørgen E Nielsen
Journal:  Genes (Basel)       Date:  2013-09-10       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.